Long-Term Therapeutic Consequences of Psychiatric Monotherapy in Severe Comorbid Illness

The growing prevalence of severe mental illness
with a comorbidity has created a major therapeutic challengein long-term management. Monotherapy has been presented as a has simplified the approach that reduces polypharmacy-related adverse events, but the clinical community have remained uncertain about its sustained effectiveness across the diverse psychiatric conditions.Although many of the controlled trials
have documented short-term benefits, a limited number of
investigations have reported whether the monotherapymaintainedstability when patients have experienced multiple comorbidities. The unclear balance between the symptom control and the functional recovery has raised the concernswith a regard to the relapse, quality of life, and the medication adherence in long-term trajectories.The present study adopted a longitudinal observational design to examine the outcomes of
monotherapy in adults diagnosed with a severe mental illness
accompanied by comorbidity. A total of 312 patients were
followed for the five years. Standardized clinical scales assessed the symptom severity, relapse frequency, social functioning, and the medication adherence. Data analysis used mixed-effect regression models to compare baseline and the follow-up observations. The findings from the studyhave indicated that the monotherapy has produced favorable yet variable outcomes across the diagnostic groups. Approximately 58% of patients have experienced stable symptom reduction, while the 27% have shown partial response, and the 15% have exhibited relapse
requiring treatment adjustments. Symptom reduction reached
21.6% at six months, with a functional improvement of 9 GAF
points and the adherence rates exceeding 90% at Month 12.
Relapse frequencyhas remained low, with a 12% at Month 6 and
the 18% at Month 12. has improved the adherence has been
observed in patients reporting has reduced the side effects, and the enhanced psychosocial functioning has been more
pronounced in individuals with a mood-related disorders than
psychotic disorders. The subgroup with a substance-use
comorbidity has experienced the highest relapse rate. Thus, the evidence indicates that long-term monotherapyhasremained
effective for a substantial proportion of patients while
necessitating individualized monitoringand the timely
interventions to prevent relapse.